JAK2-Exon 12 Mutational Analysis
Although most cases of polycythemia vera (PV) has the p.V617F activating mutation in the JAK2 tyrosine kinase, a small proportion of PV cases may have mutations (usually deletions) in exon 12.
PCR-based Sanger sequencing of DNA is performed to examine mutational status of exon 12 of JAK2.
Tumor clones must comprise at least 20% of the cells in the sample for accurate assessment.
- 10 ml peripheral blood, 2-5mL bone marrow aspirate, 5ug purified DNA,
- 4-10 unstained tissue sections on glass slides along with 1 H&E-stained sections.
Please provide a copy of the corresponding pathology report.
Additional charges will apply for tissue extraction.
The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.